The estimated Net Worth of Michael R Hayden is at least $60 Milion dollars as of 22 September 2023. Michael Hayden owns over 20,000 units of Ionis Pharmaceuticals Inc stock worth over $56,284,074 and over the last 10 years he sold IONS stock worth over $2,550,000. In addition, he makes $1,146,300 as Independent Director at Ionis Pharmaceuticals Inc.
Sign up
Michael Hayden IONS stock SEC Form 4 insiders trading
Michael has made over 26 trades of the Ionis Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of IONS stock worth $98,200 on 22 September 2023.
The largest trade he's ever made was exercising 270,000 units of Ionis Pharmaceuticals Inc stock on 13 September 2021 worth over $4,787,100. On average, Michael trades about 22,179 units every 60 days since 2014. As of 22 September 2023 he still owns at least 1,323,397 units of Ionis Pharmaceuticals Inc stock.
You can see the complete history of Michael Hayden stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Hayden biography
Dr. Michael R. Hayden, Ph.D., is Independent Director of the Company. Dr. Hayden is a Killam Professor at the University of British Columbia and the Director of the Translational Laboratory in Genetic Medicine at the National University of Singapore and the Agency for Science, Technology and Research (A*STAR). From 2012 to 2017, he served as President of Global R&D and Chief Scientific Officer at Teva Pharmaceutical Industries Ltd. Dr. Hayden has founded three biotechnology companies and has been the recipient of numerous prestigious honors and awards, including being inducted into the Canadian Medical Hall of Fame, receiving the July 2012 Diamond Jubilee Medal, on behalf of HRH Queen Elisabeth II and the Margolese National Brain Disorder Prize, awarded to Canadians who have made outstanding contributions to the treatment, amelioration or cure of brain diseases. He has also received the Canada Gairdner Wightman award for his outstanding leadership in medicine and medical science as a physician-scientist. Dr. Hayden was awarded the Order of Canada, the Order of British Columbia, named Canada’s Health Researcher of the Year by Canadian Institutes of Health Research, and has received the Prix Galien Award for his contribution to Canadian pharmaceutical research. Dr. Hayden has served on the boards of Aurinia Pharmaceuticals since February 2018 and Xenon Pharmaceuticals since November 1996, both public biopharmaceutical companies. The Board believes Dr. Hayden is uniquely suited to serve on the Board because he has significant expertise in pharmaceutical research and development, both in academia and in commercial settings. In addition, Dr. Hayden has made substantial research contributions to advance treatments for brain diseases, which is particularly valuable as we grow our neurology franchise.
What is the salary of Michael Hayden?
As the Independent Director of Ionis Pharmaceuticals Inc, the total compensation of Michael Hayden at Ionis Pharmaceuticals Inc is $1,146,300. There are 14 executives at Ionis Pharmaceuticals Inc getting paid more, with Stanley Crooke having the highest compensation of $9,598,830.
How old is Michael Hayden?
Michael Hayden is 68, he's been the Independent Director of Ionis Pharmaceuticals Inc since 2018. There are 4 older and 21 younger executives at Ionis Pharmaceuticals Inc. The oldest executive at Ionis Pharmaceuticals Inc is Breaux Castleman, 79, who is the Independent Director.
What's Michael Hayden's mailing address?
Michael's mailing address filed with the SEC is 2855 GAZELLE COURT, , CARLSBAD, CA, 92010.
Insiders trading at Ionis Pharmaceuticals Inc
Over the last 9 years, insiders at Ionis Pharmaceuticals Inc have traded over $32,069,332 worth of Ionis Pharmaceuticals Inc stock. The most active insiders traders include Stanley T Crooke, B Lynne Parshall oraz Michael R Hayden. On average, Ionis Pharmaceuticals Inc executives and independent directors trade stock every 8 days with the average trade being worth of $445,289. The most recent stock trade was executed by Richard S Geary on 28 August 2024, trading 651 units of IONS stock currently worth $32,159.
What does Ionis Pharmaceuticals Inc do?
ionis pharmaceuticals, inc., located in the north san diego county city of carlsbad, was founded in 1989 to create advanced, novel medicines to treat complex and challenging diseases. we are the pioneer in the discovery and development of antisense drugs with more than 1300 patents. ionis is a challenging, motivating and rewarding environment designed to foster innovation and scientific excellence. our founding goals have changed little in over 27 years and our success is a direct result of our outstanding employees. we are interested in bringing together individuals with different skill sets into this creative environment to be part of a productive team. join us and experience our unique culture while you develop and expand your career. for more information about ionis and to apply for an open position, please visit our website: www.ionispharma.com.
What does Ionis Pharmaceuticals Inc's logo look like?
Complete history of Michael Hayden stock trades at Aurinia Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, Xenon Pharmaceuticals Inc, 89bio Inc oraz AbCellera Biologics
Ionis Pharmaceuticals Inc executives and stock owners
Ionis Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Stanley Crooke,
Executive Chairman of the Board of Directors -
Brett Monia,
Chief Executive Officer, Director -
Richard Geary,
Senior Vice President - Development -
Elizabeth Hougen,
Senior Vice President, Finance and Chief Financial Officer -
Patrick O'Neil,
Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary -
Joan Herman,
Director -
B. Lynne Parshall,
Director -
Dr. Brett P. Monia Ph.D.,
Founder, CEO & Director -
Dr. Stanley T. Crooke,
Scientific Advisor -
Joseph Klein,
Independent Director -
Joseph Wender,
Independent Director -
Spencer Berthelsen,
Independent Director -
Breaux Castleman,
Independent Director -
Frederick Muto,
Independent Director -
Michael Hayden,
Independent Director -
Joseph Loscalzo,
Independent Director -
Peter Reikes,
Independent Director -
B. Lynne Parshall Esq., J.D.,
Sr. Strategic Advisor & Director -
C. Frank Bennett,
Chief Scientific Officer -
Dr. Richard S. Geary,
Exec. VP & Chief Devel. Officer -
Elizabeth L. Hougen,
Exec. VP of Fin. & CFO -
Patrick R. O'Neil Esq.,
Chief Legal Officer, Gen. Counsel & Corp. Sec. -
Dr. Eric E. Swayze Ph.D.,
Exec. VP of Research -
D. Wade Walke,
Investor Relations -
Onaiza Cadoret-Manier,
Chief Corporate Development and Commercial Officer -
Eric Swayze,
Senior Vice President - Research -
Dr. C. Frank Bennett,
Exec. VP & Chief Scientific Officer -
Darren Gonzales,
Chief Accounting Officer & Sr. VP -
Joel Edwards,
VP of Corp. Operations -
Damien Mc Devitt,
Chief Business Officer -
Sarah Boyce,
Chief Business Officer -
Joseph Baroldi,
EVP, Chief Business Officer -
Kyle Jenne,
EVP, Chf GL Pdt Str Ofcr -
Allene M. Diaz,
Director -
Brian Birchler,
EVP, Corp and Development Ops -
Eugene Schneider,
EVP, Chf Clinical Develop Ofcr -
Michael J. Yang,
Director